Iovance Biotherapeutics (NASDAQ:IOVA) has been assigned a $16.00 target price by stock analysts at HC Wainwright in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 49.53% from the stock’s current price.
Several other research firms also recently commented on IOVA. BidaskClub downgraded shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 22nd. Oppenheimer set a $13.00 price target on shares of Iovance Biotherapeutics and gave the stock a “buy” rating in a research note on Thursday, October 12th. Jefferies Group restated a “buy” rating on shares of Iovance Biotherapeutics in a report on Sunday, October 29th. FBR & Co restated a “buy” rating and issued a $17.50 target price on shares of Iovance Biotherapeutics in a report on Wednesday, October 25th. Finally, Zacks Investment Research upgraded shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a report on Tuesday, October 17th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $14.72.
Iovance Biotherapeutics (IOVA) traded up $1.07 during mid-day trading on Wednesday, hitting $10.70. 1,736,591 shares of the company’s stock traded hands, compared to its average volume of 586,738. The stock has a market capitalization of $777.17, a P/E ratio of -8.17 and a beta of 4.89. Iovance Biotherapeutics has a 52-week low of $4.45 and a 52-week high of $11.35.
Several institutional investors have recently modified their holdings of the company. Legal & General Group Plc bought a new stake in Iovance Biotherapeutics in the second quarter valued at $103,000. Parametric Portfolio Associates LLC bought a new stake in Iovance Biotherapeutics in the second quarter valued at $125,000. Dynamic Technology Lab Private Ltd bought a new stake in Iovance Biotherapeutics in the third quarter valued at $133,000. People s United Financial Inc. bought a new stake in Iovance Biotherapeutics in the second quarter valued at $143,000. Finally, Edge Wealth Management LLC bought a new stake in Iovance Biotherapeutics in the third quarter valued at $150,000. Hedge funds and other institutional investors own 75.93% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Iovance Biotherapeutics (IOVA) PT Set at $16.00 by HC Wainwright” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2018/01/19/iovance-biotherapeutics-iova-pt-set-at-16-00-by-hc-wainwright.html.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.